2.915
price down icon5.35%   -0.165
 
loading
Prokidney Corp stock is traded at $2.915, with a volume of 357.65K. It is down -5.35% in the last 24 hours and up +335.97% over the past month. ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$3.08
Open:
$3.07
24h Volume:
357.65K
Relative Volume:
0.03
Market Cap:
$438.95M
Revenue:
-
Net Income/Loss:
$-35.47M
P/E Ratio:
-5.114
EPS:
-0.57
Net Cash Flow:
$-124.27M
1W Performance:
-4.42%
1M Performance:
+335.97%
6M Performance:
+82.21%
1Y Performance:
+24.06%
1-Day Range:
Value
$2.86
$3.07
1-Week Range:
Value
$2.86
$3.50
52-Week Range:
Value
$0.4603
$7.13

Prokidney Corp Stock (PROK) Company Profile

Name
Name
Prokidney Corp
Name
Phone
336-999-7028
Name
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Name
Employee
204
Name
Twitter
Name
Next Earnings Date
2024-12-09
Name
Latest SEC Filings
Name
PROK's Discussions on Twitter

Compare PROK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PROK
Prokidney Corp
2.91 438.95M 0 -35.47M -124.27M -0.57
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.51 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
555.34 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.84 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
593.41 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.75 31.54B 3.81B -644.79M -669.77M -6.24

Prokidney Corp Stock (PROK) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-30-25 Downgrade BofA Securities Neutral → Underperform
Sep-30-24 Initiated JP Morgan Neutral
Sep-10-24 Initiated Guggenheim Buy
Mar-07-24 Resumed Morgan Stanley Equal-Weight
Jan-02-24 Downgrade BofA Securities Buy → Neutral
Jul-25-23 Initiated BTIG Research Buy
Dec-21-22 Initiated Jefferies Buy
Nov-10-22 Initiated Morgan Stanley Equal-Weight
Oct-18-22 Initiated UBS Buy
Oct-14-22 Initiated Citigroup Buy
Sep-23-22 Initiated BofA Securities Buy
Sep-02-22 Initiated Evercore ISI Outperform
View All

Prokidney Corp Stock (PROK) Latest News

pulisher
Jul 28, 2025

Does ProKidney Corp. stock perform well during market downturnsBuild wealth with reliable stock picks - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are the technical indicators suggesting about ProKidney Corp.AI Powered Forecasts With Proven Results - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Is ProKidney Corp. stock overvalued or undervaluedAI Powered Entry Points That Work - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Is it the right time to buy ProKidney Corp. stockOutstanding investment returns - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

ProKidney Shares Double on Strong Phase 2 Data for Kidney Disease Therapy - MSN

Jul 27, 2025
pulisher
Jul 27, 2025

Key External Factors That Drive ProKidney Corp. Stock Price MovementsFree Stock Market Group - metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

Is ProKidney Corp. a growth stock or a value stockBuild a diversified portfolio for risk management - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What makes ProKidney Corp. stock price move sharplyHigh-profit capital plays - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How volatile is ProKidney Corp. stock compared to the marketCapitalize on emerging growth stocks - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are ProKidney Corp. company’s key revenue driversInvest smarter and grow your wealth faster - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

ProKidney Stock Skyrockets But Greensboro Is Still Empty Handed - Rhino Times

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about ProKidney Corp. stockUnmatched profit potential - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Is ProKidney Corp. a good long term investmentFree Capital Allocation Plans - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Published on: 2025-07-25 13:32:55 - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Meet the Biotech Stock That Rocketed 775% Higher - AOL.com

Jul 24, 2025
pulisher
Jul 24, 2025

Prokidney’s REACT Study: A Promising Step for Kidney Disease Treatment - TipRanks

Jul 24, 2025
pulisher
Jul 23, 2025

What drives ProKidney Corp. stock priceHigh-octane financial growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

BlackRock, Inc. Reduces Stake in ProKidney Corp: A Strategic Por - GuruFocus

Jul 23, 2025
pulisher
Jul 23, 2025

ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement - MSN

Jul 23, 2025
pulisher
Jul 21, 2025

11 Best High Return Penny Stocks to Buy Now - Insider Monkey

Jul 21, 2025
pulisher
Jul 20, 2025

JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK) - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

ProKidney Corp. Stock Analysis and ForecastDynamic profit expansion - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

JP Morgan Maintains Neutral Stance on ProKidney Corp., Citing Extended Timeline for Key Data - AInvest

Jul 20, 2025
pulisher
Jul 20, 2025

ProKidney Corp. (PROK): Navigating Clinical Pivotality and Market Volatility in the Race for a CKD Breakthrough - AInvest

Jul 20, 2025
pulisher
Jul 19, 2025

New Strong Buy Stocks for July 17th - MSN

Jul 19, 2025
pulisher
Jul 18, 2025

10 Hot Penny Stocks to Invest in Now - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

ProKidney Shares Dip Following FDA Agreement on Rilparencel Approval Strategy - MSN

Jul 18, 2025
pulisher
Jul 17, 2025

PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN

Jul 17, 2025
pulisher
Jul 17, 2025

This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy? - Mitrade

Jul 17, 2025
pulisher
Jul 17, 2025

Best Momentum Stocks to Buy for July 17th - Nasdaq

Jul 17, 2025
pulisher
Jul 17, 2025

PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study - MSN

Jul 17, 2025
pulisher
Jul 17, 2025

ProKidney gains pivotal therapy advancement step with FDA - Winston-Salem Journal

Jul 17, 2025

Prokidney Corp Stock (PROK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$22.68
price down icon 1.78%
$37.00
price down icon 0.16%
$102.73
price up icon 0.99%
$27.03
price down icon 1.09%
$111.86
price down icon 0.82%
biotechnology ONC
$301.76
price up icon 2.26%
Cap:     |  Volume (24h):